Screening for vitamin D deficiency: a systematic review for the U.S. Preventive Services Task Force

• Published in: Annals of internal medicine Vol. 162; no. 2; p. 109
• Main Authors: LeBlanc, Erin S, Zakher, Bernadette, Daeges, Monica, Pappas, Miranda, Chou, Roger
• Format: Journal Article
• Language: English
• Published: United States 20.01.2015
• Subjects: Accidental Falls - prevention & control; Asymptomatic Diseases; Calcium - therapeutic use; Dietary Supplements; Fractures, Bone - prevention & control; Homes for the Aged; Humans; Institutionalization; Mass Screening; Mortality; Risk Assessment; Treatment Outcome; United States; Vitamin D - adverse effects; Vitamin D - analogs & derivatives; Vitamin D - blood; Vitamin D - therapeutic use; Vitamin D Deficiency - diagnosis; Vitamin D Deficiency - drug therapy
• DOI: 10.7326/M14-1659

Vitamin D deficiency has been associated with adverse health outcomes. To systematically review benefits and harms of vitamin D screening in asymptomatic adults. Ovid MEDLINE (through the third week of August 2014), Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. Randomized trials of screening for and treatment of vitamin D deficiency and case-control studies nested within the Women's Health Initiative. One investigator abstracted data, a second reviewed data for accuracy, and 2 investigators independently assessed study quality using predefined criteria. No study examined the effects of vitamin D screening versus no screening on clinical outcomes. Vitamin D treatment was associated with decreased mortality versus placebo or no treatment (11 studies; risk ratio [RR], 0.83 [95% CI, 0.70 to 0.99]), although benefits were no longer seen after trials of institutionalized persons were excluded (8 studies; RR, 0.93 [CI, 0.73 to 1.18]). Vitamin D treatment was associated with possible decreased risk for having at least 1 fall (5 studies; RR, 0.84 [CI, 0.69 to 1.02]) and falls per person (5 studies; incidence rate ratio, 0.66 [CI, 0.50 to 0.88]) but not fractures (5 studies; RR, 0.98 [CI, 0.82 to 1.16]). Vitamin D treatment was not associated with a statistically significant increased risk for serious adverse events (RR, 1.17 [CI, 0.74 to 1.84]). Variability across studies in 25-hydroxyvitamin D assays and baseline levels, treatment doses, use of calcium, and duration of follow-up. Treatment of vitamin D deficiency in asymptomatic persons might reduce mortality risk in institutionalized elderly persons and risk for falls but not fractures. Agency for Healthcare Research and Quality.